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Abstract
Objectives: This study was conducted to compare overall survival (OS) in patients presenting with
isolated hepatic metastases with that of patients with synchronous metastatic disease to the liver and
sarcomatosis on a background of gastrointestinal stromal tumours (GISTs).
Methods: Patients presenting with metastatic GISTs during 1999–2009 were identified. Survival out-
comes were compared between groups.
Results: Of the 193 patients with GISTs, 43 patients presented with isolated hepatic metastases and 16
presented with synchronous metastases to the liver and sarcomatosis. Thirteen patients with metastases
to the liver and sarcomatosis underwent surgery, and 34 patients with metastatic disease solely to the
liver underwent hepatic resection. The proportion of patients treated with preoperative tyrosine kinase
inhibitor (TKI) therapy was similar in both groups. Similar OS was observed in both groups (isolated liver
metastases group: 40.5 months; liver metastases and sarcomatosis group: 28.7 months; P = 0.620).
Conclusions: Overall survival in patients with GIST and metastatic disease to the liver and sarcomatosis
is similar to that in patients with isolated metastatic liver disease. Although patients with a greater disease
burden might be expected to show worse survival, these data do not reflect this assumption.
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Introduction
Current recommendations for patients presenting with localized
or potentially resectable gastrointestinal stromal tumours (GISTs)
include complete excisionwithmicroscopically negativemargins if
surgery can be performed with acceptable rates of morbidity.1,2 In
patients presenting with locally advanced tumours or metastatic
disease, treatment with tyrosine kinase inhibitors (TKIs), specifi-
cally imatinib mesylate (Gleevec™; Novartis Pharma AG, Basel,
Switzerland) is initiated with the intention of reducing tumour
burden and thereby enhancing the patient’s chances for complete
and curative resection.3 After initiation of therapy, patients are
assessed at short intervals to determine therapeutic effect. Non-
responders, especially those with documented mutations in KIT
exon 9, may benefit from dose escalation4–6 of imatinib mesylate
depending upon clinical tolerance, whereas others may benefit
from approved second-line therapy with sunitinib malate.7
This approach of preoperative TKI therapy followed by resec-
tion in patients with localized disease is based on observations of
different investigators: patients with stable or responsive tumours
achieved 12-month overall survival (OS) of 95% in one study8 and
2-year actuarial survival approaching 100% in another.9 Further-
more, recent data for patients with metastatic GIST limited to the
liver that required hepatectomy showed that combination therapy
comprised of surgical resection and neoadjuvant TKI therapy was
This manuscript was presented at the annual AHPBA meeting, Miami, 7–11
March 2012.
DOI:10.1111/hpb.12011 HPB
HPB 2013, 15, 655–660 © 2012 International Hepato-Pancreato-Biliary Association
more effective than surgery or TKI therapy alone.10 Nevertheless,
the benefit of surgery in patients with metastatic GIST to the liver
and sarcomatosis remains unclear. To date, no definitive data exist
to prove whether surgical intervention in addition to TKI therapy
improves clinical outcomes in these patients. For these reasons,
this study was designed to test the hypothesis that similar survival
benefits can be obtained in patients with isolated metastatic
disease to the liver and those with metastatic disease to the liver
and sarcomatosis. A prospectively maintained database of all
GIST patients who presented at a tertiary centre was used for this
analysis.
Materials and methods
The Institutional Review Board at Moffitt Cancer Center, in
Tampa, Florida, USA, approved all aspects of this research. For the
present study, electronic medical records included in a prospec-
tively maintained database of patients presenting with pathologi-
cally confirmed GIST were retrospectively reviewed. Patients in
this analysis comprised all consecutive patients treated at the study
institution from January 1999 to December 2009.
Demographic data on age at diagnosis, gender, race, tumour
size at presentation and location of the primary tumour were
recorded. Location of the primary tumour was categorized
as: stomach; duodenum; jejunum/ileum; colon/rectum; perito-
neum, or unknown. For the purpose of analysis, patients with
metastatic disease isolated to the liver were compared with
patients with metastases in the liver and sarcomatosis. Patients
with sarcomatosis included those with metastatic disease affecting
the peritoneum, omentum, colon, pancreas, spleen or any other
intra-abdominal location in addition to the liver. Final pathologic
margin status after the initial operation was defined as R0 for
microscopically negative resection, R1 for microscopically positive
resection or R2 for grossly positive resection. The use of neoad-
juvant TKI therapy was documented in both study groups.
Recorded variables included type of TKI or chemotherapy
regimen used, duration of neoadjuvant TKI therapy in months,
and evidence of tolerance determined by the need for regimen
conversion (i.e. from imatinib mesylate to sunitinib malate).
Recurrent disease was determined by cross-sectional imaging after
a gross margin-negative primary tumour resection. Follow-up
and OS were recorded from the date of diagnosis to the date of last
clinical follow-up or death.
Descriptive statistics were measured using sas Version 9.31
(SAS Institute, Inc., Cary, NC, USA). The Kaplan–Meier method
was used to estimate OS. A Fisher’s or chi-squared test was used
when indicated to determine significant differences between
groups. A P-value of <0.05 was considered to indicate statistical
significance.
Results
A total of 193 patients with biopsy-proven GIST were identified in
the database. Of these, patients with localized disease at presenta-
tion (n = 134) were excluded from the final analysis. The remain-
ing 59 patients with documented metastatic disease within the
abdominal cavity at presentation were included in this study. Of
these, 43 patients had metastatic disease isolated to the liver (LM-
only group) and 16 had liver metastases and sarcomatosis (LM +
S group). In the latter group, metastatic disease was located in the
liver and colon (n = 1), liver and omentum (n = 1), liver and
mesentery (n = 8), and liver and peritoneum (n = 6). Patient
demographics were similar in both groups (Table 1). In this series,
most patients were male and White.
The most common location of the primary tumour in the
LM-only group was the stomach. The primary source of disease
could not be identified in most patients in whom metastatic
disease was present synchronously in both the liver and other
intra-abdominal locations (Table 2). In patients in whom the
location of the primary tumour was known, no differences in the
size of the primary tumour were noted. A similar proportion of
patients in each group underwent surgery to remove the metas-
tases, whether these were liver-only or included liver and other
intra-abdominal locations, with equivalent rates of microscopi-
cally negative margins in both groups (LM-only group: n = 20,
47%; LM + S group: n = 7, 44%; P = 0.700). Rates of recurrence
after surgery were also similar (LM-only group: n = 16, 37%; LM
+ S group: n = 8, 50%; P = 0.080). Median follow-up was 29.9
months in the LM-only group and 26.3 months in the LM + S
group (P < 0.450).
Neoadjuvant TKI therapy was given to similar proportions of
patients in both groups (Table 3). Eighteen of all 59 patients
received neoadjuvant therapy. One patient in the LM + S group
had been treated with two different regimens of cytotoxic chemo-
therapy prior to referral to the study institution. Patients with
Table 1 Demographic characteristics of study groups
Characteristic LM-only group LM + S group P-value
(n = 43) (n = 16)
Age at diagnosis, years, median 65 61 0.480
Gender
Male 56% 69% 0.070
Female 44% 31%
White 75% 78% 0.710
LM-only, liver metastases in isolation; LM + S, liver metastases and sarcomatosis.
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tumours that demonstrated radiographic evidence of progression
during treatment with imatinib mesylate were subsequently
treated with sunitinib malate. The duration of neoadjuvant TKI
therapy was similar in both groups (LM-only group: 18 months;
LM + S group: 17 months; P = 0.400).
Kaplan–Meier analysis showedmedianOSof 40.5months in the
LM-only group and 28.7months in the LM + S group (Fig. 1). The
difference between groups did not reach statistical significance.
Discussion
The number of patients presenting with advanced GIST is signifi-
cant,11 with some studies showing incidence rates of up to 47% at
the time of diagnosis.12 This heterogeneous group of patients
includes those with unresectable primary lesions, locally advanced
disease with metastases within the abdominal cavity, patients with
metastatic disease present at extra-abdominal locations, and
patients with sarcomatosis. In patients with metastatic disease
limited to the abdomen, the liver and peritoneal cavity (sarcoma-
tosis) are the most common locations.1 Current consensus recom-
mendations for these individuals include the initiation of TKI
therapy with frequent imaging surveillance to assess for therapeu-
tic response.2 When favourable response or the stabilization of
disease has been achieved, aggressive surgical resection and/or
metastasectomy may result in the complete excision of disease;
however, a large number of patients will experience recurrence
within 2 years13,14 and it is generally accepted that resection alone
is seldom a successful treatment strategy. In patients with non-
responsive tumours and in those in whom amacroscopically com-
plete resection is not feasible, changing the treatment regimens or
enrolling the patient in a clinical trial with an alternative novel
agent should be considered as potential options.15,16
To date, however, the most widely accepted indication for
surgery in patients with non-responsive disease is for palliation of
complications with debulking performed for bleeding, perfora-
tion, obstruction, intractable pain or fistula formation resulting
Table 2 Primary tumour location and oncologic outcomes in patients with liver metastases and patients with liver metastases and
sarcomatosis
LM-only group LM + S group P-value
(n = 43) (n = 16)
Primary tumour location, n
Stomach 20 4 0.003
Duodenum 7 1 0.040
Jejunum 5 1 0.210
Unknown 11 10 0.001
Tumour size, cm, median 7.6 9 0.140
Surgical resection of metastatic lesion(s), n 34 13 0.850
R0 resectiona, n 20 7 0.700
Recurrence, n 16 8 0.080
Recurrence site, n
Liver only 14 2 0.004
Liver and other locationb 2 6 0.004
aR0 resection refers to microscopic negative margins.
bOther locations included peritoneum, mesentery, kidney and lumbar spine.
LM-only, liver metastases in isolation; LM + S, liver metastases and sarcomatosis.
Table 3 Neoadjuvant therapy in patients with liver metastases and patients with liver metastases and sarcomatosis
LM-only group LM + S group P-value
(n = 43) (n = 16)
Neoadjuvant therapy, n
Imatinib mesylate only 8 1 0.001
Imatinib + sunitinib malate 6 2 0.390
Chemotherapya 0 1 0.001
Duration of neoadjuvant TKI therapy, months 18 17 0.400
aOne patient received cytotoxic chemotherapy in the form of mesna, doxorubicin, ifosfamide and dacarbazine, followed by three cycles of
cyclophosphamide, doxorubicin and vincristine.
LM-only, liver metastases in isolation; LM + S, liver metastases and sarcomatosis; TKI, tyrosine kinase inhibitor.
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from advanced GIST. Nevertheless, this approach to non-
responsive disease has recently been challenged by the findings of
small studies that show acceptable postoperative outcomes in
patients in whom neoadjuvant TKI therapy failed to provide
tumour growth control.17,18 A retrospective study by Hasegawa
and colleagues reported that the use of surgery to remove residual
foci of active disease following TKI therapy was associated with
OS of 100% at 1 year and 75% at 2 years postoperatively in
carefully selected patients.19 More recently, Mussi et al. found
5-year disease-specific survival of 67% in patients submitted to
surgical excision after proving to have focal progression following
neoadjuvant TKI therapy.20 Others, however, have suggested that
surgical outcomes and survival correlate with tumour responsive-
ness to TKI therapy at the time of surgery.8,21
One clear limitation of the present study concerns its inability
to accurately determine tumour response to neoadjuvant TKI
therapy prior to the patient’s presentation at the study institution.
This is mainly a result of the referral patterns affecting the study
population. Patients were generally started on TKI therapy when
they were first diagnosed with metastatic GIST and this often
occurred prior to referral to the study centre.Another drawback of
the current analysis is that it refers to a relatively low number of
patients treated with neoadjuvant TKI therapy prior to surgical
exploration. The standardization of neoadjuvant TKI therapy in
patients presenting with locally advanced or metastatic GISTs was
introduced only in themid-2000s, which explains in part why only
30% of the patients included in the current analysis, which refers
to the period of 1999–2009, received TKIs prior to being consid-
ered for surgical intervention.At the study institution, patients are
discussed by a multidisciplinary team and TKI therapy is initiated
after the pathologic specimen has been reviewed and the patient is
deemed a reasonable candidate for medical therapy. Patients are
then followed closely with cross-sectional imaging until the
maximal response to TKI therapy is achieved. If the medical con-
dition of the patient permits, curative resection is then attempted
in the setting of maximal disease response or at least in the
absence of multifocal progression. Postoperatively, patients are
continued on TKI therapy according to previously published














30 40 50 60 70 80 90 100
Liver metastases only









15 12 12 8 7 7 6 4 3 1 1 LM + S group
41 39 31 24 22 16 14 14 14 14 LM-only group
Figure 1 Overall survival from date of diagnosis in patients with liver metastases only (LM-only group) and patients with liver metastases and
sarcomatosis (LM + S group). Median overall survival: LM-only group, 40.5 months; LM + S group, 28.7 months (P = 0.620)
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guidelines.2 Although the length of adjuvant TKI therapy has not
been investigated in prospective randomized studies, there is
emerging evidence to support the benefit of continuing TKI
therapy for at least 36 months in patients with high-risk
tumours.22 Despite the limitations of the present study, the finding
of similar longterm survival benefits in patients presenting with
isolated liver metastases and patients with liver metastases and
sarcomatosis might provide new insights into the management of
these complex patients.
In patients with metastatic disease limited to the liver, recent
data have shown promising results when hepatectomy is com-
bined with adjuvant TKI therapy. In a retrospective review of 39
patients submitted to hepatectomy for metastatic disease followed
by adjuvant TKI therapy, Turley and colleagues10 foundOS rates of
96.7%, 76.8% and 67.9% at 1 year, 2 years and 3 years, respectively.
Rates of severe complications and postoperative mortality were
10.2% and 2.5%, respectively.10 When controlling for confound-
ers, postoperative TKI therapy was associated with improved sur-
vival. The authors concluded that these findings indicate that
combination therapy for GIST liver metastases comprised of sur-
gical resection and TKI therapy is more effective than surgery or
TKI therapy alone.10
In patients with a more extensive hepatic disease burden, other
liver-directed techniques have not had uniform success and most
studies have been limited to small case series or case reports. For
example, Jones et al. reported their experience using radiofre-
quency ablation in 13 patients with progression in a single liver
lesion but stable disease elsewhere.23 The MD Anderson Cancer
Center group reported its experience of using transarterial chem-
oembolization (TACE) with a combination of cisplatin and vin-
cristine in 110 patients with documented metastatic GIST and
cited a partial response rate of 14%, stable disease in 74% of
patients and progressive disease after treatment in 12%.24 Rates of
progression-free survival in the liver were 31%, 8% and 5% at 1,
2 and 3 years, respectively, and OS rates were 62%, 32% and 20%
at 1, 2 and 3 years, respectively. In this study, extensive liver
involvement, the presence of extrahepatic metastases, and pro-
gression of liver disease after TACE were associated with poor
OS.24 Use of imatinib mesylate prolonged OS time in this series.24
More recently, the same group reported survival benefits of
chemoembolization to the liver in 14 patients with imatinib-
resistant GIST treated with prolonged TKI therapy and noted to
have unresectable disease.25 Further research is needed to deter-
mine the optimal timing of liver-directed therapies and TKI
therapies.
In conclusion, the present study shows that patients with GIST
metastatic to the liver and sarcomatosis at presentation achieve OS
similar to that in patients with isolated metastatic liver disease.
Although patients with a greater disease burden might be
expected to demonstrate worse survival, these data do not reflect
this assumption. Whether this finding results from systemic
therapy alone or its combination with aggressive debulking
surgery remains unknown.
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